Disclaimer
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.

Cash Dividend Announcement for Equity Issuer	
Issuer name	Grand Pharmaceutical Group Limited
Stock code	00512
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	Final dividend for the year ended 31 December 2021
Announcement date	17 March 2022
Status	New announcement
Information relating to the dividend	
Dividend type	Final
Dividend nature	Ordinary
For the financial year end	31 December 2021
Reporting period end for the dividend declared	Not applicable
Dividend declared	HKD 0.11 per share
Date of shareholders' approval	To be announced
Information relating to Hong Kong share register	
Default currency and amount in which the dividend will be paid	HKD 0.11 per share
Exchange rate	HKD 1 : HKD 1
Ex-dividend date	06 June 2022
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	07 June 2022 16:30
Book close period	From 08 June 2022 to 08 June 2022
Record date	08 June 2022
Payment date	21 June 2022
Share registrar and its address	Computershare Hong Kong Investor Services Limited Shops 1712-1716, 17th Floor, Hopewell Centre 183 Queen’s Road East Wanchai Hong Kong
Information relating to withholding tax	
Details of withholding tax applied to the dividend declared	Not applicable

Information relating to listed warrants / convertible securities issued by the issuer	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
Other information	
Other information	Not applicable
Directors of the issuer	
The Board comprises four executive directors, namely, Dr. Tang Weikun, Dr. Shao Yan, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent non- executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.	